Results for requiring corneal graft surgery translation from English to Danish

episalvan was studied in two main studies involving 217 patients with partial-thickness skin wounds in patients who underwent skin graft surgery.
episalvan blev undersøgt i to hovedundersøgelser med deltagelse af 217 patienter, som havde delhudssår og fik foretaget hudtransplantation.

dynastat has been studied in dental, orthopaedic, gynaecologic (principally hysterectomy) and coronary artery bypass graft surgery.
dynastat er undersøgt ved tandkirurgi, ortopædkirurgi, gynækologisk kirurgi (især hysterektomi) og koronar bypassoperation.

in cure there was no excess in major bleeds with clopidogrel plus asa within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
i cure var der ikke overrepræsentation af større blødninger med clopidogrel plus asa inden for 7 dage efter koronar bypass hos patienter, der seponerede behandlingen mere end 5 dage før indgrebet.

in cure, there was no excess in major bleeds with clopidogrel plus asa within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
i cure var der ikke overrepræsentation af større blødninger med clopidogrel plus asa inden for

following coronary artery bypass graft surgery, patients administered dynastat have a higher risk of adverse events, such as cardiovascular/ thromboembolic events, deep surgical infections and sternal wound healing complications.
efter koronar bypassoperation har patienter, der får dynastat en øget risiko for uønskede hændelser som f. eks. kardiovaskulære/ tromboemboliske hændelser, dybe sårinfektioner og sternale sårhelingskomplikationer.

in patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel+asa, and 6.3% for placebo+asa.
hos patienter, som fortsatte med behandlingen indtil 5 dage før bypassoperationen, var forekomsten 9,6 % for clopidogrel+asa og 6,3 % for placebo+asa.

artery bypass graft surgery or coronary angioplasty) by 37% (p = 0.009) and coronary angiography by 31% (p = 0.007).
bypass- transplantat eller koronar angioplastik) med 37% (p = 0, 009) og koronar angiografi med 31% (p = 0, 007).

the following undesirable effects had a rate greater than placebo and have been reported among 1543 patients administered dynastat 20 or 40 mg as a single or multiple dose (up to 80 mg/ day) in 12 placebo controlled studies, including dental, gynaecologic, orthopaedic surgery or coronary artery bypass graft surgery as well as pre-operative administration in dental and orthopaedic surgeries.
følgende bivirkninger havde en hyppighed større end placebo og er set blandt 1543 patienter, der har fået dynastat 20 mg eller 40 mg som en enkelt eller flere doser (op til 80 mg/ dag) i 12 placebokon - trollerede undersøgelser, inklusive tandkirurgi, gynækologisk kirurgi, ortopædkirurgi eller koronar bypassoperation såvel som præ- operativ administration ved tandkirurgi og ortopædkirurgi.